New Jersey S 2024: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Status: Approved P.L.2016, c.73. (as of 2016-12-05)

State: New Jersey · Session: 217 · Bill: S 2024

Subjects: DRUG ABUSE, REGULATORY

Sponsors: Benson, Daniel R., Conaway, Herb, Eustace, Tim, Madden, Fred H., McKnight, Angela V., Mukherji, Raj, Oroho, Steven V., Peterson, Erik, O'Scanlon, Declan J., Pinkin, Nancy J.

View New Jersey S 2024 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.